Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | PREP | P48147 | 4/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.33 |
| ▸ | FEN1 | P39748 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2641955 | 0.79 | PREP (0.43) | CA12CA1CA9PREP | |
| SCHEMBL1727022 | 0.79 | CA12 (0.41) | CA12CA1CA9PREPALOX5AP | |
| SCHEMBL30277881 | 0.79 | PREP (0.43) | CA12CA1CA9PREP | |
| SCHEMBL29790285 | 0.79 | CA12 (0.41) | CA12CA1CA9PREPALOX5AP | |
| SCHEMBL19924498 | 0.78 | ALOX5AP (0.43) | CA12CA1CA9PREPALOX5AP | |
| SCHEMBL6855170 | 0.78 | CA12 (0.41) | CA12CA1CA9PREPALOX5AP | |
| SCHEMBL13534994 | 0.78 | CA12 (0.41) | CA12CA1CA9PREPALOX5AP | |
| SCHEMBL29875070 | 0.78 | ALOX5AP (0.43) | CA12CA1CA9PREPALOX5AP | |
| SCHEMBL17316564 | 0.77 | PREP (0.38) | CA12CA1CA9PREPALOX5AP | |
| SCHEMBL6763899 | 0.77 | PREP (0.53) | CA12CA1CA9PREPALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CENTAURUS THERAPEUTICS (US) | 2026-03-12 | — | — | US | disclosed |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2025-03-11 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| CN-111787916-B | Dihydroceramide desaturase inhibitors for treating diseases | 森陶鲁斯治疗公司 | 2023-09-05 | — | — | CN | disclosed |
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-03-07 | — | — | US | disclosed |
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-03-07 | — | — | US | disclosed |
| EP-3737361-A1 | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE | Centaurus Therapeutics (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200339535-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2020-10-29 | — | — | US | disclosed |
| US-20200339535-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2020-10-29 | — | — | US | disclosed |
| CN-111787916-A | Inhibitors of dihydroceramide desaturase for the treatment of diseases | 森陶鲁斯治疗公司 | 2020-10-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, SMPD1, ASAH1 | CA12 3943/4885CA1 2374/4885CA9 3198/4885 |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CERS2, DEGS1, CERT1 | CA12 3456/4885CA1 3703/4885CA9 1239/4885 |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, SMPD1, ASAH1 | CA12 3943/4885CA1 2374/4885CA9 3198/4885 |
| US-20200339535-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CERS2, SMPD1, ASAH1 | CA12 3943/4885CA1 2374/4885CA9 3198/4885 |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CERS2, SMPD1, ASAH1 | CA12 3943/4885CA1 2374/4885CA9 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.